|1.||Jayaram, Hiremagalur N: 3 articles (07/2002 - 04/2002)|
|2.||Jayaram, H N: 2 articles (07/2013 - 01/2001)|
|3.||Lavrnja, Irena: 2 articles (04/2008 - 06/2005)|
|4.||Stojkov, Danijela: 2 articles (04/2008 - 06/2005)|
|5.||Mostarica-Stojkovic, Marija: 2 articles (04/2008 - 09/2002)|
|6.||Stosic-Grujicic, Stanislava: 2 articles (04/2008 - 09/2002)|
|7.||Szekeres, Thomas: 2 articles (03/2005 - 04/2002)|
|8.||Wright, Daniel G: 2 articles (11/2004 - 11/2004)|
|9.||Malek, Karim: 2 articles (11/2004 - 11/2004)|
|10.||Waraska, Kristin: 2 articles (11/2004 - 11/2004)|
01/01/1992 - "Tiazofurin is effective in treating end-stage leukemic patients (Tricot et al., Cancer Res 49:3696-3701, 1989). "
11/01/1986 - "Previous studies have attributed this difference to a depressed capacity to synthesize TAD on the part of tumors refractory to tiazofurin. "
10/01/1985 - "Tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide), a new nucleoside antimetabolite, was evaluated in a phase I trial involving children with refractory cancers. "
05/15/2006 - "Remarkably, compound 2 was found to be 570-fold more potent than tiazofurin against MCF-7 cells, while compound 3 showed the most powerful cytotoxicity against HT-29 cancer cells, being almost 100-fold more active than tiazofurin."
05/15/1993 - "Tiazofurin exhibits antitumor activity in murine and human tumor cells. "
04/01/2002 - "However, in tiazofurin (TR), a related drug, phase I/II clinical trials have been conducted in patients with acute leukemia and shown to be a very promising agent with a response rate of 85% in 26 patients in one of the trials. "
05/15/1993 - "In a recent phase I/II trial in patients with end-stage leukemia, tiazofurin showed good response; however, repeated treatment resulted in clinical resistance to the drug. "
05/08/1992 - "In our study, 26 patients with end-stage leukemia were treated with tiazofurin with 1-hr daily i.v. infusions, resulting in lower incidence and less severity of side effects. "
11/01/2004 - "K562 leukemia cell growth was studied relative to IMPDH expression and activity following culture of the cells with Tiazofurin, an IMPDH inhibitor. "
11/01/2004 - "Although these hematologic responses were transient, persisting less than 3-4 weeks, our findings confirm that Tiazofurin has anti-leukemia activity. "
|3.||Blast Crisis (Blast Phase)
12/03/1993 - "Tiazofurin (TR), a potent and specific inhibitor of this enzyme, proved to be effective in the treatment of refractory granulocytic leukemia in blast crisis. "
07/01/2007 - "Tiazofurin, a potent IMPDH inhibitor, reached clinical trials with Orphan Drug status for the treatment of patients in blast crisis of chronic myelogenous leukemia (CML); however, it was considered too toxic for application against other malignancies and no development has been reported for this drug since 2002. "
08/01/1988 - "These studies show that K 562 cells are sensitive to selective inhibition of de novo guanylate pathway indicating that human chronic myelogenous leukemia in blast crisis might be a good candidate for Phase II clinical trials with tiazofurin."
11/01/1996 - "Tricot et al have reported that the nucleoside analog tiazofurin can induce hematologic remissions in patients with chronic myelogenous leukemia in blast crisis (CML-BC). "
11/01/1996 - "Twenty-seven patients with end stage leukemia or myeloid blast crisis of CGL were treated with tiazofurin. "
01/01/1992 - "This study illustrates the potential usefulness of tiazofurin in treating human colon carcinoma."
01/01/1999 - "In human ovarian carcinoma OVCAR-5 cells in growth inhibition assay, the IC50s (drug concentration that inhibits 50% of cell proliferation) for tiazofurin and QN were (mean +/- SE) 13 +/- 1.2 and 66 +/- 3.0 microM; in clonogenic assays they were 6 +/- 0.5 and 15 +/- 1.2 microM, respectively. "
01/01/1999 - "Because tiazofurin and QN attack different biochemical targets and arrest different phases of the cell cycle, we tested the hypothesis that the two drugs might be synergistic against human carcinoma cells. "
01/01/1992 - "Antitumor activity of tiazofurin in human colon carcinoma HT-29."
11/01/1996 - "Antiinvasive effects of Tiazofurin on liver-metastatic human colon carcinoma xenografts."
|5.||Lewis Lung Carcinoma
08/01/1987 - "Resistance of cultured Lewis lung carcinoma cell lines to tiazofurin."
01/01/1988 - "Advanced Lewis lung carcinoma cured by tiazofurin as a system to study delayed hemopoietic effects of cancer."
01/01/1984 - "Tiazofurin is an interesting drug now entering Phase I trials, with marked preclinical antitumor activity against P388 and L1210 leukemias, and the Lewis lung carcinoma. "
06/01/1985 - "Tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, TCAR, Riboxamide, NSC 286193) is a novel C-nucleoside with antitumor activity against several murine tumor models, including Lewis lung carcinoma. "
08/01/1987 - "An established in vitro cell line (LLTC), originally derived from the Lewis lung carcinoma (LL), was found to have lost sensitivity to the C-nucleoside antitumor agent tiazofurin (NSC-286193; 2-beta-D-ribofuranosylthiazole-4-carboxamide) both in vitro and in vivo. "
|4.||Folic Acid (Vitamin M)
|5.||Guanosine Triphosphate (GTP)
|6.||acivicin (AT 125)
|8.||thiazole-4-carboxamide adenine dinucleotide (TCAD)
|9.||Inosine Monophosphate (IMP)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Combination Drug Therapy (Combination Chemotherapy)